
    
      A non randomized study ,plans to enrollment 24 patients of B cell lymphoma ，divided into low,
      medium and high dose groups，to evaluate the safety and tolerability of CD19-BCMA CAR - T
      cells immunotherapy in patients with relapsed or refractory B cell lymphoma ，to evaluate the
      preliminary efficacy and observe PK/PD parameters of CD19-BCMA CAR - T cells immunotherapy in
      patients with relapsed or refractory multiple myeloma .
    
  